Last reviewed · How we verify
GT-220F capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GT-220F capsule (GT-220F capsule) — Geode Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GT-220F capsule TARGET | GT-220F capsule | Geode Therapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GT-220F capsule CI watch — RSS
- GT-220F capsule CI watch — Atom
- GT-220F capsule CI watch — JSON
- GT-220F capsule alone — RSS
Cite this brief
Drug Landscape (2026). GT-220F capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/gt-220f-capsule. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing